Kindeva Drug Delivery

Activities: Drug Delivery Pharmaceutical

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
  5. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

Related Content

Manufacturing

Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer

Denis will be responsible for optimising global operations for the company

Kindeva Drug Delivery appoints Jennifer Riter as Vice President of Analytical Services

Riter comes to Kindeva from West Pharmaceutical, where she spent the past 27 years in various technical and leadership roles
Drug Delivery

Kindeva Drug Delivery launches new analytical services global business unit

They launch a new global business unit offering integrated and stand-alone analytical support to the wider pharmaceutical, biopharmaceutical and medical device sector
Finance

Kindeva Drug Delivery acquires Summit Biosciences

Kindeva Drug Delivery has acquired Summit Biosciences, an intranasal drug delivery contract development and manufacturing organisation (CDMO), from its founding family shareholders
Sustainability

Kindeva Drug Delivery and Orbia Fluorinated Solutions (Koura) announce low GWP propellant collaboration

This partnership aims to facilitate the conversion of pMDI products to the lower GWP propellent 152a and progressing them through clinical development
Manufacturing

Kindeva receives government fund towards green pressurised metered-dose inhalers

The CDMO has received £33m (USD $41.9m) from the UK government’s Life Sciences Innovation Manufacturing Fund to continue delivering ever-evolving therapies for respiratory diseases
Drug Delivery

Meridian set for $100m sterile fill-finish expansion in US

Following the recent Kindeva merger, the US-based autoinjector expert has planned to convert the new 155,000 sqft facility
Subscribe now